| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Potential support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Randomized, controlled Phase II ongoing |
Top-line data for Phase II Q1-24 | |||
| Moderate knee osteoarthritis | $7B | Phase I/II ongoing |
Randomized, controlled Phase I/II expected Q1 2024 |
Top-line data for Phase I/II Q2-25 | |||
| End-stage knee osteoarthritis $2B Phase I/II | $2B | Phase I/II ongoing |
Top-line data for Phase I/II Q2-24 | ||||
Pipelinemonimono2023-11-26T13:41:27+03:00
